Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Blue Cross & Blue Shield of MississippiAll Plans · Coverage · Medical Policy · Pulmonology, Oncology, PathologyMedium impact

Molecular Testing in the Management of Pulmonary Nodules

Effective date
Not stated in the notice
Identified
Jun 20, 2026

Summary

Plasma-based proteomic screening, including Nodify XL2 (BDX-XL2) and Nodify CDT, in individuals with undiagnosed pulmonary nodules detected by computed tomography is considered investigational. The policy history records a 10/14/2026 update that removed information on the REVEAL Lung Nodule Characterization and Percepta Bronchial Genomic Classifier tests, removed the REVEAL Lung Nodule Characterization by MagArray because the company is no longer in business, and removed the investigational statement for the Percepta Genomic Sequencing Classifier because that product is no longer marketed.

Get alerts when payers change rules like this one

We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.

Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.

What to do

Action · 2 steps
01Billing team: Before billing plasma-based proteomic screening (Nodify XL2 or Nodify CDT) for individuals with undiagnosed pulmonary nodules detected by computed tomography, note that the policy considers this screening investigational and not considered medically necessary.
02The policy lists CPT 83520 and 84999 under Investigational Codes.

Codes mentioned

8352084999

Original notice

Molecular Testing in the Management of Pulmonary Nodules
bcbsms.com · Always check the source before changing claims.
View original ↗

Related changes

See all Blue Cross & Blue Shield of Mississippi changes →
Miscellaneous Genetic and Molecular Diagnostic TestsMediumEffective Jul 1, 2025 · Medical PolicySomatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Non-Small-Cell Lung Cancer (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS, NTRK)MediumNo effective date · Medical PolicyIntracellular Micronutrient AnalysisMediumNo effective date · Medical PolicyLaboratory and Genetic Testing for Use of 5-Fluorouracil in Patients With CancerMediumNo effective date · Medical PolicyBrowse every Blue Cross & Blue Shield of Mississippi change in the policy list

Related policy hubs

Blue Cross & Blue Shield of Mississippi policiesPulmonologyOncologyPathologyCode 83520Code 84999

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account